Intra-Cellular Therapies, Inc. Presents New Data From The Phase 2 Clinical Trial Of ITI-007 In Schizophrenia At The 167th Annual Meeting Of The American Psychiatric Association

NEW YORK, May 6, 2014 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders is presenting additional data from the Phase 2 clinical trial of ITI-007 in schizophrenia at the 167th Annual Meeting of the American Psychiatric Association (APA) being held in New York, NY.

Help employers find you! Check out all the jobs and post your resume.